HOMER3

Summary

HOMER3 (homer scaffold protein 3, HGNC:17514) is a protein-coding gene on chromosome 19p13.11, encoding Homer protein homolog 3 (Q9NSC5). Postsynaptic density scaffolding protein.

This gene encodes a member of the HOMER family of postsynaptic density scaffolding proteins that share a similar domain structure consisting of an N-terminal Enabled/vasodilator-stimulated phosphoprotein homology 1 domain which mediates protein-protein interactions, and a carboxy-terminal coiled-coil domain and two leucine zipper motifs that are involved in self-oligomerization. The encoded protein binds numerous other proteins including group I metabotropic glutamate receptors, inositol 1,4,5-trisphosphate receptors and amyloid precursor proteins and has been implicated in diverse biological functions such as neuronal signaling, T-cell activation and trafficking of amyloid beta peptides. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 9454 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 84 total
• MANE Select transcript: NM_004838

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17514
Approved symbol	HOMER3
Name	homer scaffold protein 3
Location	19p13.11
Locus type	gene with protein product
Status	Approved
Aliases	HOMER-3
Ensembl gene	ENSG00000051128
Ensembl biotype	protein_coding
OMIM	604800
Entrez	9454

Gene structure

Transcript identifiers

Ensembl transcripts: 20 — 18 protein_coding, 2 retained_intron

ENST00000221222, ENST00000392351, ENST00000433218, ENST00000539827, ENST00000542541, ENST00000594439, ENST00000594794, ENST00000595756, ENST00000596482, ENST00000599097, ENST00000599808, ENST00000600077, ENST00000861160, ENST00000861161, ENST00000861162, ENST00000936392, ENST00000936393, ENST00000971943, ENST00000971944, ENST00000971945

RefSeq mRNA: 4 — MANE Select: NM_004838 NM_001145721, NM_001145722, NM_001145724, NM_004838

CCDS: CCDS12391, CCDS46022, CCDS46023

Canonical transcript exons

ENST00000392351 — 10 exons

Exon	Start	End
ENSE00001113523	18929203	18929634
ENSE00001122610	18934303	18934410
ENSE00001182908	18938728	18938884
ENSE00001223641	18938353	18938484
ENSE00001511549	18938969	18939049
ENSE00002301558	18941051	18941217
ENSE00003520895	18932924	18933045
ENSE00003542404	18931976	18932132
ENSE00003562658	18931509	18931625
ENSE00003608757	18931325	18931411

Expression profiles

Bgee: expression breadth ubiquitous, 277 present calls, max score 97.29.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 29.9560 / max 292.2226, expressed in 1750 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
180117	27.2904	1747
180116	1.3913	869
180115	0.5449	363
180114	0.4006	213
180113	0.3288	159

Top tissues by expression

294 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cerebellar vermis	UBERON:0004720	97.29	gold quality
right hemisphere of cerebellum	UBERON:0014890	96.54	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	96.30	gold quality
spleen	UBERON:0002106	96.04	gold quality
cerebellar cortex	UBERON:0002129	95.47	gold quality
hindlimb stylopod muscle	UBERON:0004252	95.40	gold quality
cerebellar hemisphere	UBERON:0002245	95.38	gold quality
spinal cord	UBERON:0002240	95.26	gold quality
gastrocnemius	UBERON:0001388	95.24	gold quality
cerebellum	UBERON:0002037	95.00	gold quality
metanephros cortex	UBERON:0010533	94.80	gold quality
muscle of leg	UBERON:0001383	94.52	gold quality
inferior vagus X ganglion	UBERON:0005363	93.91	gold quality
stromal cell of endometrium	CL:0002255	93.64	gold quality
ganglionic eminence	UBERON:0004023	93.17	gold quality
right lobe of thyroid gland	UBERON:0001119	93.11	gold quality
left lobe of thyroid gland	UBERON:0001120	93.06	gold quality
muscle organ	UBERON:0001630	92.74	gold quality
monocyte	CL:0000576	92.68	gold quality
paraflocculus	UBERON:0005351	92.60	gold quality
thyroid gland	UBERON:0002046	92.16	gold quality
mononuclear cell	CL:0000842	91.94	gold quality
leukocyte	CL:0000738	91.50	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	91.24	gold quality
ascending aorta	UBERON:0001496	91.02	gold quality
thoracic aorta	UBERON:0001515	90.91	gold quality
skin of leg	UBERON:0001511	90.54	gold quality
endocervix	UBERON:0000458	90.49	gold quality
right adrenal gland cortex	UBERON:0035827	90.18	gold quality
gluteal muscle	UBERON:0002000	90.17	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-MTAB-8271	yes	15.77
E-CURD-114	yes	10.17
E-ANND-3	yes	7.60

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CEBPA

miRNA regulators (miRDB)

13 targeting HOMER3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-22-3P	99.93	68.13	917
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-8067	99.86	69.59	2260
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-1915-3P	99.58	66.79	1988
HSA-MIR-376A-3P	99.06	69.17	1128
HSA-MIR-376B-3P	99.06	69.17	1128
HSA-MIR-3928-5P	98.50	67.48	980
HSA-MIR-6806-3P	98.50	67.31	980
HSA-MIR-6773-5P	97.04	64.30	595
HSA-MIR-6724-5P	96.41	63.11	507
HSA-MIR-4743-5P	88.08	64.31	91

Literature-anchored findings (GeneRIF, showing 10)

• Homer-3 may be involved in the regulation of SRE activation in T cells via interaction between its EVH1 domain and C/EBP beta. (PMID:14645007)
• Fat1 exhibit co-localisation with Homer-3 in cellular protrusions and at the plasma membrane of HeLa cells (PMID:16979624)
• study found that Homer2 and Homer3 are negative regulators of T cell activation; this is achieved through binding of nuclear factor of activated T cells (NFAT) and by competing with calcineurin (PMID:18218901)
• Homer3 specifically associates with a novel ubiquitin-like domain in the I kappa B kinase (IKK) beta subunit of the IKK complex. (PMID:20693425)
• Loss of Homer3 is associated with acute myeloid leukemia. (PMID:23725168)
• Interaction of the protein with amyloid precursor protein is regulated by calcium homeostasis. (PMID:24792907)
• Homer3 acts as a scaffold that spatially organizes actin assembly to support neutrophil polarity and motility downstream of GPCR activation. (PMID:25739453)
• HOMER3 facilitates growth factor-mediated beta-Catenin tyrosine phosphorylation and activation to promote metastasis in triple negative breast cancer. (PMID:33407765)
• Glycoproteomics identifies HOMER3 as a potentially targetable biomarker triggered by hypoxia and glucose deprivation in bladder cancer. (PMID:34108014)
• HOMER3 promotes liver hepatocellular carcinoma cancer progression by -upregulating EZH2 and mediating miR-361/GPNMB axis. (PMID:38266459)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	homer3b	ENSDARG00000010789
danio_rerio	homer3a	ENSDARG00000102532
mus_musculus	Homer3	ENSMUSG00000003573
rattus_norvegicus	Homer3	ENSRNOG00000020229

Paralogs (2): HOMER2 (ENSG00000103942), HOMER1 (ENSG00000152413)

Protein

Protein identifiers

Homer protein homolog 3 — Q9NSC5 (reviewed: Q9NSC5)

All UniProt accessions (5): Q9NSC5, M0QYF9, M0QZN1, M0R2T8, M0R2U7

UniProt curated annotations — full annotation on UniProt →

Function. Postsynaptic density scaffolding protein. Binds and cross-links cytoplasmic regions of GRM1, GRM5, ITPR1, DNM3, RYR1, RYR2, SHANK1 and SHANK3. By physically linking GRM1 and GRM5 with ER-associated ITPR1 receptors, it aids the coupling of surface receptors to intracellular calcium release. Isoforms can be differently regulated and may play an important role in maintaining the plasticity at glutamatergic synapses. Negatively regulates T cell activation by inhibiting the calcineurin-NFAT pathway. Acts by competing with calcineurin/PPP3CA for NFAT protein binding, hence preventing NFAT activation by PPP3CA.

Subunit / interactions. Tetramer. Isoform 1 and isoform 2 encode coiled-coil structures that mediate homo- and heteromultimerization. Interacts with NFATC2; interaction is calcium independent; interaction competes with PPP3CA for NFATC2 binding; interaction is reduced by AKT activation. Interacts with NFATC1 and NFATC4. Interacts with SHANK1; forms a high-order complex at least composed of SHANK1 and HOMER3; the complex formation is regulated by CAMK2A-mediated phosphorylation.

Subcellular location. Cytoplasm. Postsynaptic density. Synapse.

Domain organisation. The WH1 domain interacts with the PPXXF motif in GRM1, GRM5, RYR1, RYR2, ITPR1, SHANK 1 and SHANK3.

Similarity. Belongs to the Homer family.

Isoforms (5)

UniProt ID	Names	Canonical?
Q9NSC5-1	1, 3a	yes
Q9NSC5-2	2
Q9NSC5-3	3, 3c
Q9NSC5-4	4, 3d
Q9NSC5-5	5

RefSeq proteins (4): NP_001139193, NP_001139194, NP_001139196, NP_004829* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000697	WH1/EVH1_dom	Domain
IPR011993	PH-like_dom_sf	Homologous_superfamily
IPR044100	Homer_EVH1	Domain
IPR045027	Homer	Family

Pfam: PF00568

UniProt features (36 total): mutagenesis site 8, strand 8, splice variant 6, turn 3, region of interest 2, helix 2, coiled-coil region 2, modified residue 2, chain 1, domain 1, sequence variant 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
2P8V	X-RAY DIFFRACTION	1.85
3CVF	X-RAY DIFFRACTION	2.9

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NSC5-F1	83.47	0.62

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 120, 159

Mutagenesis-validated functional residues (8):

Position	Phenotype
22	does not affect interaction with nfatc2. decreases interaction with nfatc2; when associated with 53-l–s-56. decreases i
30–31	markedly decreases interaction with nfatc2; when associated with s-43 and 53-l–s-56. markedly decreases interaction wit
36	does not affect interaction with nfatc2; when associated with a-38 and a-52. attenuates inhibition by akt; when associat
38	does not affect interaction with nfatc2; when associated with a-36 and a-52. attenuates inhibition by akt; when associat
43	does not affect interaction with nfatc2. decreases interaction with nfatc2; when associated with n-22 and 53-l–s-56. ma
52	does not affect interaction with nfatc2; when associated with a-36 and a-38. attenuates inhibition by akt; when associat
53–56	decreases interaction with nfatc2. decreases interaction with nfatc2; when associated with n-22. decreases interaction w
54	decreases interaction with nfatc2.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-6794361	Neurexins and neuroligins

MSigDB gene sets: 192 (showing top): TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_UP, MULLIGHAN_NPM1_SIGNATURE_3_UP, GOBP_REGULATION_OF_CALCIUM_MEDIATED_SIGNALING, GOBP_REGULATION_OF_SYNAPTIC_TRANSMISSION_GLUTAMATERGIC, GOBP_PROTEIN_TARGETING, DARWICHE_SKIN_TUMOR_PROMOTER_UP, DARWICHE_PAPILLOMA_RISK_LOW_UP, DARWICHE_PAPILLOMA_RISK_HIGH_UP, CROONQUIST_NRAS_SIGNALING_UP, DARWICHE_SQUAMOUS_CELL_CARCINOMA_DN, GOBP_G_PROTEIN_COUPLED_GLUTAMATE_RECEPTOR_SIGNALING_PATHWAY, GOBP_MONOATOMIC_CATION_TRANSPORT, GOBP_CELL_CELL_SIGNALING, GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_SUSTAINDED_IN_ERYTHROCYTE_UP

GO Biological Process (6): protein targeting (GO:0006605), G protein-coupled glutamate receptor signaling pathway (GO:0007216), negative regulation of interleukin-2 production (GO:0032703), regulation of synaptic transmission, glutamatergic (GO:0051966), negative regulation of calcineurin-NFAT signaling cascade (GO:0070885), regulation of store-operated calcium entry (GO:2001256)

GO Molecular Function (4): protein domain specific binding (GO:0019904), G protein-coupled glutamate receptor binding (GO:0035256), identical protein binding (GO:0042802), protein binding (GO:0005515)

GO Cellular Component (8): cytoplasm (GO:0005737), cytosol (GO:0005829), plasma membrane (GO:0005886), postsynaptic density (GO:0014069), dendrite (GO:0030425), basal part of cell (GO:0045178), glutamatergic synapse (GO:0098978), synapse (GO:0045202)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Protein-protein interactions at synapses	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
protein binding	2
establishment of protein localization	1
G protein-coupled receptor signaling pathway	1
glutamate receptor signaling pathway	1
G protein-coupled glutamate receptor activity	1
negative regulation of cytokine production	1
interleukin-2 production	1
regulation of interleukin-2 production	1
synaptic transmission, glutamatergic	1
modulation of chemical synaptic transmission	1
calcineurin-NFAT signaling cascade	1
regulation of calcineurin-NFAT signaling cascade	1
negative regulation of calcineurin-mediated signaling	1
store-operated calcium entry	1
regulation of calcium ion transport	1
G protein-coupled receptor binding	1
glutamate receptor binding	1
binding	1
intracellular anatomical structure	1
cytoplasm	1
membrane	1
cell periphery	1
asymmetric synapse	1
postsynaptic specialization	1
neuron projection	1
dendritic tree	1
synapse	1
cell junction	1

Protein interactions and networks

STRING

984 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
HOMER3	SHANK1	Q9Y566	917
HOMER3	GRM1	Q13255	902
HOMER3	ITPR1	Q14643	898
HOMER3	DLGAP1	P78335	883
HOMER3	GRM5	P41594	851
HOMER3	DLG4	P78352	736
HOMER3	SHANK3	Q9BYB0	712
HOMER3	SYNGAP1	Q96PV0	664
HOMER3	ARHGAP26	Q9UNA1	602
HOMER3	NCDN	Q9UBB6	595
HOMER3	ACTN1	P12814	590
HOMER3	HOMER2	Q9NSB8	587
HOMER3	SHANK2	Q9UPX8	583
HOMER3	DNER	Q8NFT8	580
HOMER3	LGI1	O95970	572

IntAct

415 interactions, top by confidence:

A	B	Type	Score
HOMER1	HOMER3	psi-mi:“MI:0915”(physical association)	0.870
MOS	HOMER3	psi-mi:“MI:0915”(physical association)	0.790
HOMER3	MOS	psi-mi:“MI:0915”(physical association)	0.790
HOMER3	PKN1	psi-mi:“MI:0915”(physical association)	0.780
EAF1	HOMER3	psi-mi:“MI:0915”(physical association)	0.780
HOMER3	EAF1	psi-mi:“MI:0915”(physical association)	0.780
PKN1	HOMER3	psi-mi:“MI:0915”(physical association)	0.780
HOMER3	ABI2	psi-mi:“MI:0915”(physical association)	0.740
ABI2	HOMER3	psi-mi:“MI:0915”(physical association)	0.740
HOMER3	HOMER3	psi-mi:“MI:0915”(physical association)	0.740
HOMER3	EIF3D	psi-mi:“MI:0915”(physical association)	0.720
USP2	HOMER3	psi-mi:“MI:0915”(physical association)	0.720
HOMER3	PSMA1	psi-mi:“MI:0915”(physical association)	0.720
HOMER3	SNRPF	psi-mi:“MI:0915”(physical association)	0.720
HOMER3	PPP1R18	psi-mi:“MI:0915”(physical association)	0.720
EIF3D	HOMER3	psi-mi:“MI:0915”(physical association)	0.720

BioGRID (213): HOMER3 (Two-hybrid), HOMER3 (Two-hybrid), HOMER3 (Two-hybrid), HOMER3 (Two-hybrid), HOMER3 (Two-hybrid), HOMER3 (Two-hybrid), HOMER3 (Two-hybrid), HOMER3 (Two-hybrid), HOMER3 (Two-hybrid), HOMER1 (Two-hybrid), POM121 (Two-hybrid), ABI2 (Two-hybrid), NEBL (Two-hybrid), EAF1 (Two-hybrid), PPP1R18 (Two-hybrid)

ESM2 similar proteins: A0A0D1E2P6, A0A0D2XVZ5, A0A0P0VG31, A0A0P1AAU8, A0A287B8J2, A2WYG9, A4QP73, B9EHT4, B9F2Y7, D0NCC1, J9VKM5, O08788, O59739, P0C7L7, P0CP26, P0CP27, P14725, P28023, P39742, P82874, P92792, Q10MW6, Q13217, Q14203, Q149L6, Q27968, Q28I38, Q54M21, Q54NS3, Q58DR2, Q5JJI4, Q5JNB5, Q5R686, Q5R6H3, Q5ZI13, Q6PCJ1, Q6YUL8, Q7ZXQ8, Q8TBM8, Q91YW3

Diamond homologs: O88801, Q2KJ56, Q86YM7, Q99JP6, Q9NSB8, Q9NSC5, Q9QWW1, Q9Z214, Q9Z2X5, Q9Z2Y3, Q5TJ65, P50551, P70460, Q2TA49

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
CAMK2A	“down-regulates activity”	HOMER3	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

84 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	68
Likely benign	2
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

1281 predictions. Top by Δscore:

Variant	Effect	Δscore
19:18929493:G:C	donor_gain	1.0000
19:18929570:T:TA	donor_gain	1.0000
19:18929630:AGGTC:A	acceptor_gain	1.0000
19:18929633:TC:T	acceptor_gain	1.0000
19:18929634:CC:C	acceptor_gain	1.0000
19:18929635:C:CC	acceptor_gain	1.0000
19:18929640:A:T	acceptor_gain	1.0000
19:18931409:CTC:C	acceptor_gain	1.0000
19:18931504:CTCA:C	donor_loss	1.0000
19:18931505:TCA:T	donor_loss	1.0000
19:18931505:TCACC:T	donor_loss	1.0000
19:18931506:CA:C	donor_loss	1.0000
19:18931506:CAC:C	donor_loss	1.0000
19:18931507:A:AC	donor_gain	1.0000
19:18931507:ACCTG:A	donor_loss	1.0000
19:18931508:C:A	donor_loss	1.0000
19:18931508:C:CC	donor_gain	1.0000
19:18931622:CCAC:C	acceptor_gain	1.0000
19:18931623:CACC:C	acceptor_gain	1.0000
19:18931624:ACC:A	acceptor_loss	1.0000
19:18931625:CCTG:C	acceptor_loss	1.0000
19:18931626:C:CA	acceptor_loss	1.0000
19:18931626:C:CC	acceptor_gain	1.0000
19:18931626:CTGTA:C	acceptor_loss	1.0000
19:18931970:CCTCA:C	donor_loss	1.0000
19:18931971:CTCA:C	donor_loss	1.0000
19:18931972:TCACC:T	donor_loss	1.0000
19:18931973:CAC:C	donor_loss	1.0000
19:18931973:CACC:C	donor_loss	1.0000
19:18931974:A:AC	donor_gain	1.0000

AlphaMissense

2330 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:18934396:G:C	F106L	1.000
19:18934396:G:T	F106L	1.000
19:18934397:A:G	F106S	1.000
19:18934398:A:G	F106L	1.000
19:18934408:A:C	F102L	1.000
19:18934408:A:T	F102L	1.000
19:18934409:A:G	F102S	1.000
19:18934410:A:G	F102L	1.000
19:18938377:A:C	F93L	1.000
19:18938377:A:T	F93L	1.000
19:18938378:A:G	F93S	1.000
19:18938379:A:G	F93L	1.000
19:18938384:A:G	L91P	1.000
19:18938384:A:T	L91Q	1.000
19:18938387:C:T	G90D	1.000
19:18938388:C:G	G90R	1.000
19:18938391:A:C	Y89D	1.000
19:18938393:A:T	V88D	1.000
19:18938412:C:G	D82H	1.000
19:18938416:C:A	W80C	1.000
19:18938416:C:G	W80C	1.000
19:18938417:C:G	W80S	1.000
19:18938418:A:G	W80R	1.000
19:18938418:A:T	W80R	1.000
19:18938423:C:T	G78E	1.000
19:18938424:C:A	G78W	1.000
19:18938424:C:G	G78R	1.000
19:18938424:C:T	G78R	1.000
19:18938425:G:C	F77L	1.000
19:18938425:G:T	F77L	1.000

dbSNP variants (sampled 300 via entrez): RS1000062098 (19:18928985 C>A), RS1000208428 (19:18936798 G>A), RS1000262151 (19:18936538 T>C), RS1000374083 (19:18930961 T>G), RS1000418128 (19:18934825 A>G), RS1000481184 (19:18941974 G>A), RS1000789075 (19:18934601 G>C), RS1000838409 (19:18939832 C>A,T), RS1000891583 (19:18931140 G>A), RS1000931303 (19:18940043 G>A), RS1001088873 (19:18940736 CAGT>C), RS1001243172 (19:18942289 C>A,G), RS1001540152 (19:18940565 G>A), RS1001720369 (19:18940488 C>A,T), RS1002072452 (19:18928992 A>C,G)

Disease associations

OMIM: gene MIM:604800 | disease phenotypes: MIM:614622

GenCC curated gene-disease

Mondo (1): keratoconus 5 (MONDO:0013830)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

38 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, increases methylation	3
Benzo(a)pyrene	decreases methylation, increases expression	2
Estradiol	affects cotreatment, decreases expression, increases expression	2
Silicon Dioxide	increases expression	2
Tobacco Smoke Pollution	increases expression, affects expression	2
FR900359	increases phosphorylation	1
methyleugenol	increases expression	1
triphenyl phosphate	affects expression	1
glycidyl methacrylate	increases expression	1
beta-lapachone	decreases expression	1
sodium arsenite	increases expression	1
cupric chloride	increases expression	1
arsenic disulfide	decreases expression	1
2-palmitoylglycerol	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	increases expression	1
LDN 193189	affects cotreatment, increases expression	1
(+)-JQ1 compound	decreases expression	1
Temozolomide	increases expression	1
Arsenic Trioxide	affects reaction, decreases expression	1
Acetaminophen	increases expression	1
Air Pollutants	affects expression, increases abundance	1
Arsenic	affects methylation	1
Caffeine	decreases phosphorylation	1
Dactinomycin	increases expression	1
Doxorubicin	decreases expression	1
Lead	decreases expression	1
Lithium	decreases expression	1
Methyl Methanesulfonate	increases expression	1
N-Nitrosopyrrolidine	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.